HRP20131021T1 - Novi 7-deazapurin nukleozidi za terapijske uporabe - Google Patents

Novi 7-deazapurin nukleozidi za terapijske uporabe Download PDF

Info

Publication number
HRP20131021T1
HRP20131021T1 HRP20131021AT HRP20131021T HRP20131021T1 HR P20131021 T1 HRP20131021 T1 HR P20131021T1 HR P20131021A T HRP20131021A T HR P20131021AT HR P20131021 T HRP20131021 T HR P20131021T HR P20131021 T1 HRP20131021 T1 HR P20131021T1
Authority
HR
Croatia
Prior art keywords
compound according
pharmaceutically acceptable
hydrogen
mixture
acceptable salt
Prior art date
Application number
HRP20131021AT
Other languages
English (en)
Croatian (hr)
Inventor
Aurelie Bourderioux
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. filed Critical Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Publication of HRP20131021T1 publication Critical patent/HRP20131021T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20131021AT 2009-04-22 2010-04-19 Novi 7-deazapurin nukleozidi za terapijske uporabe HRP20131021T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Publications (1)

Publication Number Publication Date
HRP20131021T1 true HRP20131021T1 (hr) 2014-01-31

Family

ID=42768153

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131021AT HRP20131021T1 (hr) 2009-04-22 2010-04-19 Novi 7-deazapurin nukleozidi za terapijske uporabe

Country Status (15)

Country Link
US (3) US9321800B2 (enExample)
EP (1) EP2421879B1 (enExample)
JP (2) JP5721275B2 (enExample)
CN (2) CN102459300B (enExample)
AU (3) AU2010238985B2 (enExample)
CA (2) CA2759131C (enExample)
DK (1) DK2421879T3 (enExample)
ES (1) ES2437917T3 (enExample)
HR (1) HRP20131021T1 (enExample)
MX (1) MX2011011160A (enExample)
NZ (2) NZ700583A (enExample)
PL (1) PL2421879T3 (enExample)
PT (1) PT2421879E (enExample)
SI (1) SI2421879T1 (enExample)
WO (1) WO2010121576A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321800B2 (en) * 2009-04-22 2016-04-26 Gilead Sciences, Inc. 7-deazapurine nucleosides for therapeutic uses
WO2011075665A2 (en) * 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2018001393A1 (en) 2016-06-29 2018-01-04 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3697800A1 (en) 2017-10-19 2020-08-26 Universiteit Gent Nucleoside analogues for the treatment of parasitic infections
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) * 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
US20220267365A1 (en) * 2019-06-18 2022-08-25 Taiho Pharmaceutical Co., Ltd. Novel phosphate ester compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof
EP4106763A1 (en) * 2020-02-17 2022-12-28 Katholieke Universiteit Leuven KU Leuven Research & Development Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
WO2023052468A1 (en) 2021-09-28 2023-04-06 Universiteit Antwerpen Nucleoside analogues for the treatment of parasitic infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
MXPA03006514A (es) * 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
BR0309581A (pt) * 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
US7169918B2 (en) * 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
JP2007509939A (ja) * 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1781101A2 (en) * 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
WO2009089804A1 (en) * 2008-01-18 2009-07-23 Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. Novel cytostatic 7-deazapurine nucleosides
AU2009271436B2 (en) * 2008-06-23 2014-04-03 Janssen Pharmaceutica Nv Piperidyl acrylamide antagonists of CCR2
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
US9321800B2 (en) * 2009-04-22 2016-04-26 Gilead Sciences, Inc. 7-deazapurine nucleosides for therapeutic uses

Also Published As

Publication number Publication date
CA2759131A1 (en) 2010-10-28
DK2421879T3 (da) 2013-11-25
SI2421879T1 (sl) 2014-01-31
HK1166325A1 (en) 2012-12-14
JP5721275B2 (ja) 2015-05-20
NZ596301A (en) 2014-10-31
AU2015205885A1 (en) 2015-09-03
US10294262B2 (en) 2019-05-21
NZ700583A (en) 2016-04-29
CN104497084A (zh) 2015-04-08
JP2015013901A (ja) 2015-01-22
US20160318970A1 (en) 2016-11-03
US9321800B2 (en) 2016-04-26
JP6087889B2 (ja) 2017-03-01
CA2966647A1 (en) 2010-10-28
HK1209129A1 (en) 2016-03-24
EP2421879A2 (en) 2012-02-29
MX2011011160A (es) 2012-01-27
WO2010121576A2 (en) 2010-10-28
US9624257B2 (en) 2017-04-18
AU2010238985B2 (en) 2015-04-23
CN104497084B (zh) 2018-06-05
ES2437917T3 (es) 2014-01-15
CA2759131C (en) 2017-06-20
US20170240584A1 (en) 2017-08-24
CN102459300A (zh) 2012-05-16
AU2015205885B2 (en) 2017-04-06
AU2017204148B2 (en) 2018-12-06
JP2012524731A (ja) 2012-10-18
AU2010238985A1 (en) 2011-12-01
US20150218201A1 (en) 2015-08-06
CN102459300B (zh) 2014-12-10
PL2421879T3 (pl) 2014-02-28
AU2017204148A1 (en) 2017-07-06
PT2421879E (pt) 2013-12-09
EP2421879B1 (en) 2013-09-04
WO2010121576A3 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
HRP20171957T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka
JP2009514870A5 (enExample)
ZA201900694B (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
HRP20201727T1 (hr) 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-d]pirimidin-7(8h)-on derivati i srodni spojevi kao cdk4 inhibitori za liječenje tumora
BR112015023705A8 (pt) compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
EA201100030A1 (ru) Пиразольные соединения 436
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2016532667A5 (enExample)
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
JP2015512943A5 (enExample)
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk
JP2012524731A5 (enExample)
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
JP2014508804A5 (enExample)
RU2014107484A (ru) ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
CL2007002919A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
EA201070599A1 (ru) Ингибиторы равновесного переносчика нуклеозидов ent1
JP2013523740A5 (enExample)